A phase I clinical study of a live attenuated Bordetella pertussis vaccine - BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Thorstensson, Rigmor ^a   Trollfors, Birger ^a   Al Tawil, Nabil ^b   Jahnmatz, Maja ^a,c   Bergström, Jakob ^a   Ljungman, Margaretha ^a   Törner, Anna ^a   Wehlin, Lena ^a   Van Broekhoven, Annie ^d   Bosman, Fons ^d   Debrie, Anne Sophie ^e,f,g,h   Mielcarek, Nathalie ^e,f,g,h   Locht, Camille ^e,f,g,h  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Q Biologicals BioIncubator   (Belgium)

^e INSERM   (France)

^f CNRS   (France)

^g UNIV LILLE   (France)

^h INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIMBRIA PROTEIN; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PLACEBO; IMMUNOGLOBULIN G; LIVE VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BORDETELLA PERTUSSIS; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EPISTAXIS; EYE PAIN; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; LOW DRUG DOSE; MALE; NASOPHARYNX; NORMAL HUMAN; NOSE OBSTRUCTION; OTALGIA; PAIN; PHASE 1 CLINICAL TRIAL; RHINORRHEA; SNEEZING; UNSPECIFIED SIDE EFFECT; BACTERIAL COUNT; BLOOD; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; IMMUNITY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; VACCINATION; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; BORDETELLA PERTUSSIS; COLONY COUNT, MICROBIAL; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; MALE; NASOPHARYNX; PERTUSSIS VACCINE; PLACEBOS; VACCINATION; VACCINES, ATTENUATED; WHOOPING COUGH; YOUNG ADULT;

EID: 84897456361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083449     Document Type: Article

References (31)

1. World Health Organization. Vaccine-preventable diseases: monitoring system. Available at: http://www.who.int/immunization-monitoring/diseases/ pertussis/en/index.html. Accessed 2013 Nov 14.
2. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334: 349-55. (Pubitemid 26049587)
3. World Health Organization (2011) Weekly epidemiological record. 86: 509-20.
4. Witt MA, Katz PH, Witt DJ (2012) Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American Outbreak. Clin Infect Dis 54: 1730-5.
5. Sheridan SL, Ware RS, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308: 454-6.
6. Cherry JD (2012) Epidemic pertussis in 2012- the resurgence of a vaccine-preventable disease. N Engl J Med 367: 785-7.
7. Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, et al. (2008) Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 47: 328-38. (Pubitemid 352013513)
8. Clark TA, Messonnier NE, Hadler SC (2012) Pertussis control: time for something new? Trends Microbiol 20: 211-3.
9. Locht C, Mielcarek N (2012) New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol 66: 121-33.
10. Hodgins DC, Shewen PE (2012) Vaccination of neonates: problems and issues. Vaccine 30: 1541-59.
11. Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, et al. (2003) Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J Immunol 170: 1504-9. (Pubitemid 36139521)
12. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
13. Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, et al. (2009) A live attenuated Bordetella pertussis candidate vaccine does not cause disseminated infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol 16: 1344-51.
14. Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C (2010) Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28: 7047-53.
15. Skerry CM, Mahon BP (2011) A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol 18: 187-93.
16. Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, et al. (2008) Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 26: 5722-7.
17. FDA. Available at http://www.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074775.htm. Accessed 2013 Nov 14.
18. R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
19. Trunz BB, Fine PEM, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-80.
20. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, et al. (2007) Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B Clin Infect Dis 45 Suppl 1: S24-8. (Pubitemid 47036021)
21. Mielcarek N, Debrie AS, Mahieux S, Locht C (2010) Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 17: 317-24.
22. Mattoo S, Cherry JD (2005) Molecular Pathogenesis, Epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18: 326-82. (Pubitemid 40548297)
23. Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, et al. (2009) Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection. APMIS 117: 660-71.
24. Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, et al. (2010) Antibody patterns to Bordetella pertussis in vaccinated (primed) and unvaccinated (unprimed young children with pertussis. Clin Vaccine Immunol 17: 741-47.
25. Huang CC, Chen PM, Kuo JK, Chiu Wh, Lin St et al. (1962) Experimental whooping cough. N Engl J Med 266: 105-11.
26. Lehar C, Jayappa H, Erskine J, Brown A, Sweeney D, et al. (2008) Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther 9: 257-62.
27. Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, et al. (2001) Immunisation against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis 183: 329-32. (Pubitemid 32066036)
28. Gruber WC, Hinson HP, Holland KL, Thompson JM, Reed GW, et al. (1993) Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 168: 1282-5. (Pubitemid 23317151)
29. Cherry JD, Gornbein J, Heininger U, Stehr K (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16: 1901-06. (Pubitemid 28473933)
30. Storsaeter J, Hallander HO, Gustafsson L, Olin P (2003) Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21: 3542-49. (Pubitemid 37338177)
31. Mielcarek N, Alonso S, Locht C (2001) Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 51: 55-69. (Pubitemid 32763072)